Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa...
-
Upload
theodora-murphy -
Category
Documents
-
view
215 -
download
1
Transcript of Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa...
![Page 1: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/1.jpg)
Conservative Management of Borderline Ovarian
Tumor Prof. Dr. Fuat Demirkıran
I.U Cerrahpaşa School of Medicine.Department of OB&GYN
Division Of Gynocol Oncol April 2013 Beirut
![Page 2: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/2.jpg)
![Page 3: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/3.jpg)
Differences in Epidemiologic Features of Serous and Mucinous BOT
Serous MucinousMore frequent in western regions
One of third bilateral
60% of them stage I disease
More frequent in eastern regions
usually unilateral
70% of them stage I disease
Intestinal (comprising 85–90%) type ** extraovarian spread in only 2% of patients. ** more frequently unilateral.
Mullerian (or endocervical) lesions type ** bilateral in as many as 40% of cases. ** coexists with pelvic endometriosis in 20 – 30% of patients, including a serous componenet
![Page 4: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/4.jpg)
![Page 5: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/5.jpg)
Non –invasive implant
Invasive implant
AFIP=Air Forces Institute of Pathology. NCI=National Cancer Institute. NIH=National Institutes of Health. MPSC=micropapillary serous carcinoma. APST=atypical proliferative serous tumour. LGSC=low-grade serous carcinoma. HGSC=high-grade serous carcinoma. *Without micropapillary pattern.
Evolution of and discrepancies in current classifications of serous borderline ovarian tumours.
micropapillary pattern Stromal Microinvasion
![Page 6: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/6.jpg)
micropapillary pattern in serous BOT
..not only morphological criteria
..associated with greater frequency of bilateral tumors
..associated with higher rate of surface involvement
..associated with higher rate of invasive peritoneal implants
![Page 7: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/7.jpg)
At serous BOT
15-40 % extra-ovarian implant
Non –invasive implant Invasive implant
Recurrance rate 8%Mortality rate %4
Peritoneal Implants
Reccurance rate 29%Mortality rate 25%
![Page 8: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/8.jpg)
İmplant Olasılığını Etkileyen Faktörler
n:457
Cusido M., Gynecol Oncol, 2007
![Page 9: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/9.jpg)
Stromal Microinvasion
In 12 series of serous BOTs with microinvasion (n=133)
Recurrence rate 15 % (20/133)
Rate of disease-related death is 6%
35% (seven of 20) with invasive disease at recurrence
Data indicate that microinvasion is a prognostic factor for serous borderline ovarian tumours.
![Page 10: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/10.jpg)
Potential prognostic factors for BOTs Prognostic factors
• SBOT with implants (worse in case of invasive implants)• Peritoneal residual disease
Debatable prognostic factors• Micropapillary patterns (but not as an independent factor)• MBOT with intraepithelial carcinoma• MBOT treated with cystectomy• SBOT with stromal microinvasion
Not prognostic factors• Nodal spread• Laparoscopic approach‡• Use of adjuvant treatment (conventional chemotherapy: platinum-based regimensand paclitaxel)• MBOT with stromal microinvasion§• Conservative treatment of SBOT; use of (re)staging surgery
![Page 11: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/11.jpg)
Treatment of BOT
![Page 12: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/12.jpg)
Conservative Surgery Fertility-sparing SurgeryConservative Surgery Fertility-sparing Surgery
Who desire to preserve fertility
unilateral bilateral tmbilateral tm
USO USO + cystectomyBilateral cystectomy
Interventions for the treatment of borderline ovariantumours (Review) The Cochrane Collaboration and published in The Cochrane Library 2010, Issue 9
USO + cystectomyBilateral cystectomy
with peritoneal staging
![Page 13: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/13.jpg)
Open abdominal surgery
![Page 14: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/14.jpg)
Endoscopic Surgery
![Page 15: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/15.jpg)
Frozen section
(28%)
![Page 16: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/16.jpg)
Conservative surgery (n: 189) and Radical Surgery (n:150) Median Follow-up 70 months
Surgery Recurence DFS
Conservative S. 40% 100%Radical 13% 85%
Conservative S. 15% 99%Radical S. 2.5% 100%
Stage In:283, 83%
Stage II-IIIN:56 , 17%
Zaneta ve ark J Clin Oncol 2001
Conservative surgery for aerly stage diseasen: 339
![Page 17: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/17.jpg)
42 pts (67%) …….USO13“ (21%)……..UC 5 “ (8 %)…….. USO CC 2 “ (4 % )………CC
Mean follow-up 44 monthsRecurrence rate 7%
n: 62
![Page 18: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/18.jpg)
![Page 19: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/19.jpg)
39 pts. with stage II-III BOT
11 of them underwent USO28 “ “ “ CYSTEC.
39 pts. with stage II-III BOT
11 of them underwent USO28 “ “ “ CYSTEC.
5 yrs. 10 yrs.
Median follow-up 57 monthsRecurrence rate 56%
![Page 20: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/20.jpg)
Recurrence rate 14% Recurrence rate 14% Recurrence rate 44% Recurrence rate 44%
Literature review of recurrence rate in advanced-stage ovarian borderline tumor (in particular with invasive
implants) with conservative treatment.
![Page 21: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/21.jpg)
The prognosis of patients with noninvasive implants remains good and conservative
surgery can be considered in such patients (if implants are totally resected).
Conservative surgery at the presence of implants
The prognosis of patients with invasive implants is much poorer in the literature.
So, it should be more reluctant to propose conservative treatment to patients with
invasive implants.
![Page 22: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/22.jpg)
Impact of Conservative Surgery on theSurvival rate
the survival of patients is not affected by the use of conservative surgery
1116 69 129 4
![Page 23: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/23.jpg)
The relation between type of conservative surgery and recurrance rate
32 stage I, 12 stage II-III
Mean follow-up 109 mounts
![Page 24: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/24.jpg)
110 unilateral salpingo-oophorectomy
50 cystectomy
24 bilateral cystectomies
5 Other combinations
Recurrance localization after conservative surgery
n:2055% in contralateral ovary40% in same ovary after cystectomy 5% in extrapelvic region
Zaneta ve ark J Clin Oncol 2001
n: 189
![Page 25: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/25.jpg)
Ovarian Stimulation and IVF after Conservative Surgery
cohort study of 19,146 subfertile womenControl group 6963 subfertile women
a median follow up of 15 years, a total of 77 ovarian malignancies were observed in the cohort (42 EOC and 35
BOT
RR was 1.67 for EOC and 4.25 for BOT
The conclusion was that IVF increases the risk of BOT.
Burger CW, Gynecol Oncol 2009
![Page 26: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/26.jpg)
Recurrence rate 19% Recurrence rate 19%
Reports on patients with a previous history of borderline ovarian tumor who underwent ovarian hyperstimulation(OS) and/or oocyte retrieval (OR) for assisted conception
![Page 27: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/27.jpg)
923/2479 patients treated by conservative surgery
95% pts. with stage I or stage II disease 5% pts with stage III disease.20 women underwent ovarian stimulation and/or IVF
The recurrence rate 16% 5 recorded disease-related deaths.
ART rate 16%Pregnancy rate 48%
![Page 28: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/28.jpg)
Conclusionyoung age at diagnosis.
high overall survival rate
80%of them early stage
conservative surgery for all stages
ovarian stimulation after surgery
![Page 29: Conservative Management of Borderline Ovarian Tumor Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol.](https://reader035.fdocuments.in/reader035/viewer/2022062801/56649e2b5503460f94b19a2c/html5/thumbnails/29.jpg)